Provincial Health Services Authority

Methods and apparatus for segmenting cell nuclei in medical images apply first and second trained machine learning algorithms. The first trained machine learning algorithm processes a medical image to provide center locations of cell nuclei depicted in the image. The second machine learning algorithm processes each of a plurality of patches of the image. Each of the patches correspond to one of the plurality of center locations. Processing each patch yields a nuclear boundary corresponding to the corresponding one of the center locations. The methods and apparatus allow associating individual pixels of the image with one or more than one nuclei and have been shown to be effective for instance segmentation of nuclei in clusters of overlapping cell nuclei.

A method for detecting a presence of at least one constituent of an analyte gas is based on Raman scattering. The method comprises: mixing a buffer gas with the analyte gas; exciting the mixture with a laser excitation beam; detecting scattered photons resulting from interaction between photons of the laser excitation beam and molecules of the analyte gas to thereby determine a spectral content of the scattered photons; and analyzing the spectral content to determine the presence of the at least one constituent.

The present disclosure relates to peptidic compounds of Formula A, A-II, A-III, B, or C, or salt or solvate thereof, compositions thereof, and methods of use thereof. The compounds of the present disclosure are useful for targeting CXCR4 for purposes such as imaging and/or therapeutics.

Lymphocytes having a suppressed autophagy gene useful in immunotherapy are disclosed. The lymphocytes can express an antigen targeting receptor such as a chimeric antigen receptor (CAR) or endogenous or engineered T-cell receptor to target cells expressing a tumor-specific antigen. Methods of making and using such lymphocytes are disclosed. Some such lymphocytes are useful in conducting CAR-T or TCR-T therapy.

A system useful for in vivo and ex vivo spectroscopy comprises a water source connected to supply water through a passage to an outlet at a flow rate sufficient to issue a laminar water jet from the outlet, a light source operative to emit a light beam that is guided to a sample by the water jet, and an analysis unit connected to receive collected light that has been emitted from the sample into the water jet and operable to analyze the collected light. Some embodiments provide endoscopes with integrated light guides.

A new composition of matter composed of engineered sequences for the expression of Fap2-derived polypeptides that provoke immunogenic responses against Fusobacterium spp. is provided. Antibodies and vaccines produced using such sequences and methods of use are also provided.

This application relates to compounds of Formula I. R 1a , R 1b and R 1c is —CO 2 H, —SO 2 H, —SO 3 H, —SO 4 H, —PO 2 H, —PO 3 H or —PO 4 H. R 2 is a linker, e.g. butylene. R 3 is a linkage, e.g. —O—, —S—, —S(O)—, S(O) 2 —, —NHC(O)—, —C(O)NH—, or 1,2,3-triazole. R4 is —(CH 2 ) 0-3 CH(R 7 )(CH 2 ) 0-3 — wherein R 7 is —(CH 2 ) 5 CH 3 or certain aromatic fused-ring systems. R 5 and R 6 are hydrogen or methyl. Each Xaa 1 (if present) is an amino acid. R X is a radiolabeling group, e.g.: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging prostate-specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).

Antimicrobial peptides (AMPs), small compounds that often exhibit broad spectrum antimicrobial activity, are garnering interest as potential therapeutics against antibiotic-resistant bacterial pathogens. Development of new AMPs is arduous due to the practical limitations of classical protein-based discovery approaches. A high throughput bioinformatics approach is described which is able to confirm identification of known AMPs from the North American bullfrog ( Rana ( Lithobates ) castebeiana ) genome, and a bioinformatics approach is used to develop new AMPs, as described herein as SEQ ID NOs: 1-178. The described AMPs exhibit antimicrobial activity against Mycobacterium smegmatis via microtitre broth dilution assays, indicating broader efficacy.

Provided are compounds and method for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat disease, including, but not limited to, cancer. In certain embodiments, the compounds inhibit DNA-PK and thus sensitize cancers to therapies such as chemotherapy and radiotherapy. Compounds provided are of Formula (I).

A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF 3 )-containing moiety configured for 19 F/ 18 F exchange or a precursor thereof; and optionally a cell-targeting domain.